Press Releases.

- Continued High Virologic Response Rates across All Treatment Arms Out through 24 weeks of Follow Up -

-Oral presentation during general session on interim RG-101 Phase II results & three posters to be presented-

- RG-101 Containing Regimen Has Potential to Reduce Harvoni®, Olysio®, or Daklinza™ Rx to 4 Week Duration -

- Additional studies on track for enrollment in H12016 with multiple data read-outs expected throughout 2016 -

-Regulus Earns $10.0 Million Milestone Payment from AstraZeneca and Achieves Key Goal for 2015-